Physician profile
Douglas E Weiner
NPI 1376556696
$15,114.71
in general payments reported to CMS, 2019-2025
50 companies · $2,341 in 2025
The $2,341 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,402 · 2020: $1,940 · 2021: $2,199 · 2022: $2,354 · 2023: $2,286 · 2024: $1,592 · 2025: $2,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,203 · Education: $16.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,203.24 |
| Education | $16.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,531.36 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $2,531.47 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,315.88 | 2019-2025 | Ofev, Jardiance, Jascayd |
| Amarin Pharma, INC. | $849.30 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $701.13 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $606.30 | 2019-2024 | Yupelri |
| Novo Nordisk INC | $438.33 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $382.46 | 2020-2025 | Tezspire, Repatha |
| Lilly USA, LLC | $351.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Grifols USA, LLC | $304.55 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $241.90 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $237.72 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $203.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.41 | 2020-2024 | Glassia |
| Insmed, INC. | $184.43 | 2024-2025 | Arikayce, Brinsupri |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.